Adaptimmune Therapeutics Plc · Q1 2022 earnings

Briefing

Reported financial results and provided a business update.

Adaptimmune reported financial results for the first quarter ended March 31, 2022. The company's revenue increased primarily due to an increase in development activities under collaboration arrangements. They had cash and cash equivalents of $89.5 million and Total Liquidity of $304.2 million as of March 31, 2022.

• Preparing the BLA and targeting submission to the US Food and Drug Administration (FDA) in Q4 2022 for the treatment of synovial sarcoma.
• Preclinical data from the next-generation SPEAR T-cell targeting MAGE-A4 incorporating IL-7 and CCL19 (ADP-A2M4N7X19), developed in collaboration with Noile-Immune, to be presented in a poster; the Company plans to file an IND for this next-generation SPEAR T-cell later this year.
• Preclinical data from tumor-infiltrating lymphocytes (TILs) incorporating IL-7 (TIL-IL7), being developed in collaboration with the Center for Cancer Immune Therapy in Denmark, to be presented in a poster; a single-center clinical trial is planned for initiation in 2022.
• The Company appointed Dr. Joanna (Jo) Brewer as its Chief Scientific Officer effective May 4.

Headline financials

Revenue & EPS history

The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company’s current operations into early 2024.